Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on Canagliflozin/Metformin XR FDC
NCT02039258Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2014
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of canagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Plasma concentration of canagliflozin and Plasma concentration of metformin. Started Jan 2014; status: completed.
02
Drugs
canagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02039258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02039258.